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Abstract
Background: PB1-F2 is a major virulence factor of influenza A. This protein is a product of an alternative reading
frame in the PB1-encoding RNA segment 2. Its presence of is dictated by the presence or absence of premature
stop codons. This virulence factor is present in every influenza pandemic and major epidemic of the 20th century.
Absence of PB1-F2 is associated with mild disease, such as the 2009 H1N1 (“swine flu”).
Results: The analysis of 8608 segment 2 sequences showed that only 8.5% have been annotated for the presence
of PB1-F2. Our analysis indicates that 75% of segment 2 sequences are likely to encode PB1-F2. Two major
populations of PB1-F2 are of lengths 90 and 57 while minor populations include lengths 52, 63, 79, 81, 87, and 101.
Additional possible populations include the lengths of 59, 69, 81, 95, and 106. Previously described sequences
include only lengths 57, 87, and 90. We observed substantial variation in PB1-F2 sequences where certain variants
show up to 35% difference to well-defined reference sequences. Therefore this dataset indicates that there are
many more variants that need to be functionally characterized.
Conclusions: Our web-accessible tool PB1-F2 Finder enables scanning of influenza sequences for potential PB1-F2
protein products. It provides an initial screen and annotation of PB1-F2 products. It is accessible at http://cvc.dfci.
harvard.edu/pb1-f2.
Background
The influenza A virus causes epidemics and pandemics [1]
in humans, other mammals and birds. The disease severity
varies significantly. Recognizing danger factors by
sequence analysis helps assess the virulence potential of a
given strain. The PB1-F2 is a key danger factor which dis-
tinguishes the major flu pandemics of the 20th century
(1918 Spanish, 1957 Asian, and 1968 Hong Kong) from
the milder 2009 H1N1 “swine flu” pandemic. The pre-
sence of this alternative reading frame protein product
helps assess virulence of emerging viruses.
PB1-F2 is encoded in an alternative reading frame of
the PB1 gene (segment 2). PB1 is an obligatory protein
product that enables viral replication, while PB1-F2 is
present in some, but not all PB1-coding sequences. It is a
pro-apoptotic factor, increasing virulence and the risk of
secondary infections [2-4]. PB1-F2 expression is blocked
in some strains due to premature stop codons [5]. PB1-
F2 increases virulence through the induction of cell
death, induction of inflammation, or polymerase activity
enhancement [6]. The 2009 H1N1 is characterized by
low virulence. It lacks PB1-F2 due to premature stop
codons. For example, a stop codon (TAA) at the nucleo-
tide position 128 of PB1 gene in A/Massachusetts/06/
2009(H1N1) truncates the potential PB1-F2 after 11
amino acids. In contrast, the virulent A/Brevig Mission/
1/1918(H1N1) strain contains codon TCA at position
128, encoding a serine at position 12 of PB1-F2. In the
PB1 reading frame, C129A is a silent mutation: both
alternative codons, GTC and GTA, encode valine at
amino acid position 43 of the PB1 protein. Variants of
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acids [5].
Since the influenza virus is an RNA virus, the identifica-
tion of PB1-F2 from heterogeneous sources (PCR pro-
ducts, complete genomes, segments, coding sequences,
and fragments) requires translation of the RNA sequence
in 3 reading frames. Candidate protein products (hereafter,
CPPs) are encoded by all potential open reading frames.
All of the potential PB1-F2 products are then identified
through their similarity between CPPs and known PB1-F2
sequences. This method was used for annotation of 64
verified entries in Swiss-Prot (with known PB1 proteins)
while two entries have protein level evidence.
We present an algorithm and web server for scanning
nucleotide sequences for the presence of functional PB1-
F2. This web tool helps researchers identify whether a
newly isolated sequences en-codes a potential PB1-F2
product.
Implementation
Data sources
Sequences were obtained from the Influenza Virus
Resource, hosted at NCBI [7]. The nucleotide sequences
were extracted from the influenza.fna file provided on
their FTP repository in the FASTA format. A set of PB1-
F2 sequences was obtained from UniProt to serve as a
reference panel. Only reviewed entries from the curated
Swiss-Prot entries were used, resulting in 64 panel
sequences. Of these 11 (17%), 2 (3%), and 51 (80%) were
of lengths 57, 87, and 90, respectively. They represent
strains isolated from humans (28 or 44%), birds (32 or
50%), swine (1 or 1.5%) and laboratory strains (3 or 4.5%).
PB1-F2 identification
CPPs were generated by translating the PB1-encoding
influenza A segment 2 nucleotide sequences in 3 reading
frames. CPPs shorter than 50 amino acids were consid-
ered negative because PB1-F2 proteins of these lengths
have been neither described nor hypothesized to exist.
To identify whether a given CPP represents PB1-F2, a
distance measure was calculated between the query
sequences and all panel members. The distance measure
was defined as the number of mismatches in a Smith-
Waterman alignment as a percentage of sequence length.
If the distance to the closest panel member is below a set
threshold, the CPP is determined to be a PB1-F2 product,
thus distinguishing it from non-PB1-F2 CPPs. The algo-
rithm uses a threshold of 40 to identify PB1-F2 products,
which was determined to be discriminatory (see Results).
Web implementation
All algorithms for this analysis were implemented in the
java programming language. The web interface is hosted
on an Apache Tomcat server, written in Java and Java
Server Pages.
Results and discussion
Of the 97,260 influenza sequence entries found in the
influenza.fna source file as of December 2009, 8608
were PB1 (segment 2) entries. After translating all 3
reading frames, and selecting sequences that begin with
methionine, and end with a stop codon, 14,637 candi-
date protein segments (CPPs) were produced with a
length between 52 and 398 amino acids.
To evaluate the distance measure selectivity across the
population of CPPs, the distances were plotted against
the sequence length (Figure 1). This revealed 2 major
populations: (1) sequences which show less than 36% dif-
ference compared to the closest panel member, repre-
senting PB1-F2 CPPs and (2) sequences with greater than
86% difference, representing non-PB1-F2 CPPs (e.g. from
other reading frames). This figure shows that a conserva-
tive cutoff of 40% is effective in distinguishing between
these populations.
Figure 1 reveals two prominent outliers, which are
caused by unique PB1-F2 open reading frames. The
CPP of length 87 and distance 68 is encoded by “defec-
tive interfering” influenza virus A/WSN (H1N1) [8]. The
second outlier is a CPP from A/shorebird/Korea/S331/
2006(H10N9), of length 295 with distance 33. This
sequence has a single nucleotide insertion at position
266 in the coding transcript, which causes a frame shift
mutation rendering PB1 nonfunctional [9]. These
sequences are therefore nonfunctional outliers.
By employing this strategy for PB1-F2 identification,
we located PB1-F2-encoding nucleotide sequences
throughout the database. Of 8608 PB1-F2 entries, 6417
were determined to encode PB1-F2 (75%). There were
731 sequences in the database that were previously
annotated as encoding PB1-F2. Therefore, there we have
newly annotated 5686 PB1 entries for the presence of
PB1-F2-encoding sequences.
Conservation analysis of PB1 sequences showed that
peptides 15PB151 and 114PB1148 are 94-100% conserved
[10]. Since the PB1-F2 start and stop codons fall within
these regions respectively, the high level of conservation
results in a limited number of PB1-F2 length variants.
This is clearly shown in Figure 1. Two major populations
of PB1-F2 are of lengths 90 and 57. Several minor popu-
lations include lengths 52, 63, 79, 81, 87, and 101. Addi-
tional possible populations include the lengths of 59, 69,
81, 95, and 106. Previously described sequences include
only lengths 57, 87, and 90. However, we have observed
substantial variation in PB1-F2 sequences where certain
variants show up to 35% difference to well-defined refer-
ence sequences. Therefore this dataset indicates that
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characterized. The inspection of multiple sequence align-
ments has shown the existence of distinct populations
that appear to represent various fitness variants. For
example, the 206 PB1-F2 sequences that are 52 AA long
form 5 major sequence subgroups while 46 sequences
that are 101 AA long form three major subgroups. More
numerous length variants (e.g. those that are 57 or 90
Figure 1 Summary of PB1-F2 sequences classified by their lengths. Upper: candidate PB1-F2 peptides show up to 35% sequence
dissimilarity compared to a panel of reference sequences from Swiss-Prot. The population with distances above 86% represents non-PB1-F2 ORF
translations. Lower: number of PB1-F2 sequences in each group length.
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analysis shows that, unfortunately, characterization of
this important virulence factor is neglected by main-
stream influenza A sequence characterization. Our web
tool is a contribution to this effort since it provides an
initial screen and annotation of PB1-F2 products and
enables further detailed analysis.
Conclusion
We have implemented the PB1-F2 analysis algorithm
and strategy as a web tool, PB1-F2 Finder. The user can
input a nucleotide sequence (either in DNA or RNA
format) with or without a FASTA header line. The
application then translates the sequence in three reading
frames, digests protein products beginning with methio-
nine, and ending with a stop codon, and assesses the
presence of PB1-F2 based upon the distance measure
described in Methods. Each of these steps is outlined in
a full report to the user. The PB1-F2 Finder tool is a
contribution to the global fight against pandemic
influenza.
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